Decitabine treatment is associated with better overall survival. (A) One-year overall survival rates in arms A, B, and C were 64.4% ± 9.1%, 73.4% ± 8.8%, and 41.0% ± 9.8%, respectively (P = .025). (B) One-year overall survival rates for patients in arms A and B (decitabine ± rhTPO; 68.2% ± 6.4%) were higher than those for patients in arm C (conventional treatment; 41.0% ± 9.8%; P = .008).